We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Adiponectin in Obese Women With T2DN and Effects by RAS Blocker

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00561704
Recruitment Status : Completed
First Posted : November 21, 2007
Last Update Posted : November 21, 2007
Sponsor:
Information provided by:

Study Description
Brief Summary:
Insulin resistance typically characterizes type 2 diabetes (T2DM) and prediabetic states and is the prominent feature of the metabolic syndrome.Adiponectin plays an important part in glucose metabolism,insulin resistance, the deterioration of renal function.we hypothesize there is a difference serum adiponectin levels between obese and non-obese women with type 2 diabetic nephropathy. Furthermore, these two groups would respond difference to the RAs blocker(Losartan).

Condition or disease Intervention/treatment
Obese Type 2 Diabetes Diabetic Nephropathy Glucose Metabolism Angiotensin II Type 1 Receptor Blockers Drug: losartan

Detailed Description:
it would be a prospective cohort study. According to BMI, all the women, aged>30yr, diagnosed type 2 diabetic nephropathy, chronic kidney disease stage range from 1 to 4, will be divided to two group. Renal function index(included SCr, GFR, et al),glucose metabolism index( fasting glucose, plasma insulin et al),and adiponectin concentration will be observed and recorded. both two groups females will accept the treatment of RAS blocker(losartan, 100mg daily, 6 month). during the study, the above mentioned parameters will also be recorded 3 month intervals. Meanwhile, any side effects would be pay attention.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 80 participants
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adiponectin in Obese Women With T2DN and Effects by RAS Blocker
Study Start Date : April 2007
Study Completion Date : October 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Intervention Details:
    Drug: losartan
    losartan, 100mg daily,

Outcome Measures

Primary Outcome Measures :
  1. GFR, HbA1c and the adiponectin concentration. [ Time Frame: 6 month ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   30 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetic nephropathy
  • CKD at stage 1~4

Exclusion Criteria:

  • Type 1 diabetes or nondiabetic renal disease
  • An elevated plasma K level.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00561704


Sponsors and Collaborators
Shanghai Jiao Tong University School of Medicine
Investigators
Principal Investigator: hui min Jin, MD shanghai No 3 people's hospital
More Information

ClinicalTrials.gov Identifier: NCT00561704     History of Changes
Other Study ID Numbers: ADL
First Posted: November 21, 2007    Key Record Dates
Last Update Posted: November 21, 2007
Last Verified: November 2007

Keywords provided by Shanghai Jiao Tong University School of Medicine:
obese female
Type 2 Diabetes
Diabetic Nephropathy
Glucose Metabolism
Angiotensin II Type 1 Receptor Blockers
Adiponectin

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Kidney Diseases
Diabetic Nephropathies
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Urologic Diseases
Diabetes Complications
Losartan
Angiotensin II Type 1 Receptor Blockers
Anti-Arrhythmia Agents
Antihypertensive Agents
Angiotensin Receptor Antagonists
Molecular Mechanisms of Pharmacological Action